Pharmaceuticals

FDA Grants Priority Review of Biologics License Application for Dupixent Add-on Maintenance for Treatment of Youth with Chronic Rhinosinusitis with Nasal Polyposis

bexib
By bexib 0 Min Read

Dupixent was previously approved for adults with chronic sinusitis with poorly controlled nasal polyposis.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Where have all the babies gone? Leaders, businessmen and economists sound the alarm about falling birth rates around the world
Next Article Overwhelming Support for Calves for a Cause at Canadian Dairy XPO – RealAgriculture
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Mexico angered by US ban on Chinese connected autos, hints at plans to use USMCA gateway
Manufacturing
Fight fraud with advanced strategies and tools
Banking
Inflation-adjusted house prices will be 1.5% below their 2022 peak. Rental price index is 8.1% below its 2022 peak
Economy
Allstate Foundation empowers young changemakers with college service grants
Insurance